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Abstract: Demographic changes are putting the healthcare industry under pressure. However, while
other industries have been able to automate their operation through robotic and autonomous systems,
the healthcare sector is still reluctant to change. What makes robotic innovation in healthcare so
difficult? Despite offering more efficient, and consumer-friendly care, the assistive robotics market
has lacked penetration. To answer this question, we have broken down the development process,
taking a market transformation perspective. By interviewing assistive robotics companies at different
business stages from France and the UK, this paper identifies new insight into the main barriers of the
assistive robotics market that are inhibiting the sector. Their impact is analysed during the different
stages of the development, exploring how these barriers affect the planning, conceptualisation and
adoption of these solutions. This research presents a foundation for understanding innovation
barriers that high-tech ventures face in the healthcare industry, and the need for public policy
measures to support these technology-based firms.
Keywords: barriers to innovation; assistive robotics; market barriers; healthcare innovation
1. Introduction
Technology has always been a vital ally for healthcare [1], from the invention of new
diagnostic capabilities and therapies to practices that improve the overall quality and cost-
effectiveness of the care delivery system. This has changed healthcare and the perception
of healthcare. More generally, technology is considered the ‘holy grail’ of public policy,
achieving outcomes at a lower cost [2]. Nevertheless, the healthcare sector and its suppliers
are not as productive as they could be at adopting new technologies.
This disparity is generally attributed to the market barriers present in the sector that
are impeding the adoption of innovations and therefore their spread. Innovations in
healthcare do not follow a linear pathway even though there is still an inclination to see
these as such [3]. Indeed, the innovation process in healthcare has been described as long,
incremental and path-dependent [4], reflecting [5] recognition of the co-evolutionary and
path-dependent nature of innovation processes more generally.
Innovations today are desperately needed. Healthcare systems worldwide are under
increasing pressure. Life expectancy has increased, from 52.6 in 1960 to 72.0 in 2016 [6], and
the last two decades have witnessed continued growth in the global population [7]. In the
European Union, despite fertility levels being below what is generally regarded as the level
necessary for a population to maintain its size [8], it is estimated that population levels
will remain relatively static (falling approximately 0.35% by 2050) due to net migration [9],
while life expectancy has increased by 2.9 years, from 77.7 in 2002 to 80.6 in 2015 [10].
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For the healthcare sector, the ageing of the population translates into many more
individuals with one or more long-term conditions, and more complex patterns of dis-
eases [11]. While shortages of qualified carers are continuously increasing [12], because
of increased constraints on the funding and resources available, governments are urged
to find alternatives to help close these gaps. To provide a more tangible example, more
than 9 million people in the EU need help getting out of bed [13], and this figure is likely
to increase. A new wave of innovations is needed if we want to provide people with
affordable and effective healthcare [14].
Based on these previously introduced challenges, the assistive robotics (AR) market is
surging, providing support to patients and care workers, in the globalisation of healthcare.
Assistive robots are shifting the model of healthcare from one focused on hospital treatment
to one that supports independent life [13]. However, despite the developments of the last
two decades, the AR market is not having the impact expected due to the current market
barriers [15].
Identifying obstacles to innovation has clear policy relevance, since addressing these
barriers could increase the population of innovators and boost the performance of current
ones [16–18]. Previous research has called for more studies on problems and challenges
surrounding innovation processes in healthcare settings [19].
By offering insights into the current barriers of the AR market, we seek to assist this
process for a market we have not seen before. The development of assistive robots for the
healthcare sector is not only an issue of technology or societal acceptance. We need to work
on the broader market barriers and ways to overcome them. Only then, entrepreneurs and
firms will be aware of the venture challenges, and governments could take measures to
support these inventions that are highly needed [20].
Consequently, this paper starts by giving an overview of the current state of this
market in Section 2. Section 3 presents the methodology. Then, drawing on the experience
of 17 firms engaged in the AR market, Section 4 explores the primary market barriers
relating to the product development process, from conceptualisation to commercialisation.
Next, we discuss the barriers and its combined effect while providing implications for
policy measures to support technology-based firms. Finally, concluding remarks and
implications for research are provided in Section 5.
2. Background
The AR market relates to robotics and autonomous systems with the primary role of
providing assistive help to carers or directly to patients in hospital, specialist care facility
or domestic healthcare settings [13]. This market excludes clinical robots (e.g., surgical
robots, [21,22]; robots for diagnosis [23] or training purposes [24]) and rehabilitation robots
(e.g., prosthesis and exoskeletons [25] and rehabilitation systems [26]). It also excludes
the sector known as service robots or robots for domestic tasks (e.g., vacuum or window
cleaning, lawn mowing) [27].
The AR market features robots that organise and deliver medication [28], that support
activities of daily living such as eating [29] or putting clothes on [30], and that can improve
hygiene [31] or the recovery process [28]. It also includes lifting and displacing aids, from
helping nurses moving the patient from bed to wheelchair or helping the elderly move
around their homes [32]. Socially assistive robots are also part of this sector, offering
patient aid in therapy rehabilitation [33]. For instance, the best-known example, Paro, is
a therapeutic seal for people with dementia [34]. Finally, AR also includes robots for the
transportation of drugs, food or other resources [35], and communication purposes [36]
(Figure 1). It is recognized that this list covers just a fraction of the various applications
and opportunities for which assistive robots are being developed in universities, research
labs, and start-up companies [37]. Figure 1 shows some visual example of AR robots.
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Figure 1. Assistive robots available in the market. (1) Care-O-bot; domestic robot assistant, (2) Cutii; telepresence robot for 
older people, (3) Leka; a therapeutic robot for children with developmental disorders, (4) Obi; robotic feeding device, (5) 
AV1; robotic avatar for users with long-term conditions, (6) Paro; therapeutic robot. 
The assistive robotic market is different from any software or hardware application, 
or even other AR technologies. Manufacturing or agricultural robots have required a focus 
on the design of the mechatronic structure. Aerial, marine and transportation robots have 
focused on autonomous navigation and object detection. On the other hand, assistive ro-
bots build around the nascent human–robot interaction field [38]. They are robots that 
interact physically with their user, continuously and autonomously monitoring their con-
dition, while supporting them in different activities. The design involves different stake-
holders, different structural systems abilities and technologies, different design processes, 
and different testing methodologies, and as a result, it produces different market barriers 
for the suppliers of this emerging industry [37–39]. 
The size of the global AR market in 2015 was over USD 200 million, with an 18.9% 
compound annual growth rate estimation from 2016 to 2024 [40]. It is characterised as a 
highly fragmented sector, driven by some small players [41]. The industry is in a nascent 
state, where start-ups are pushing with an increasing number of robotic products that 
perform a wide variety of tasks [41]. 
However, despite the potential for the technology, there is limited evidence of AR 
projects that transform into new products and services for the user [38]. The International 
Federation of Robotics registered only around 5305 robotics solutions for supporting el-
derly and handicapped sold in 2016 in the world [27]. 
Furthermore, from February 2019 to March 2019, we contacted 11 robotic companies in 
the field, inquiring their trending activities (Table 1). Only one was currently supplying to the 
European market, and three were trading outside the EU. One of these 11 businesses, the 
American company Jibo Inc., who raised nearly USD 72.7 M with his social assistive robot [42], 
was forced to sell its assets in December 2018 and has been out of business since then. 
  
Figure 1. Assistive robots available in the market. (1) Care-O-bot; domestic robot assistant, (2) Cutii; telepresence robot
for older people, (3) Leka; a therapeutic robot for children with developmental disorders, (4) Obi; robotic feeding device,
(5) AV1; robotic avatar for users with long-term conditions, (6) Paro; therapeutic robot.
The assistive robotic market is different from any software or hardware application,
or even other AR technologies. Manufacturing or agricultural robots have required a focus
on the design of the mechatronic structure. Aerial, marine and transportation robots have
focused on autonomous navigation and object detection. On the other hand, assistive robots
build around the nascent human–robot interaction field [38]. They are robots that interact
physically with their user, continuously and autonomously monitoring their condition,
while supporting them in different activities. The design involves different stakeholders,
different structural systems abilities and technologies, different design processes, and
different testing methodologies, and as a result, it produces different market barriers for
the suppliers of this emergin i dustry [37–39].
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Table 1. Trading activities of assistive robotic companies contacted from February 2019 to March 2019. (Note: – indicates
that the company did not share the information, * year that the relevant robotics division was created).
Company Year Founded Total Funding Amount (* M$) Product Currently Trading
SONY * 1990 – AIBO Worldwide
Intuition Robotics 2015 22 ElliQ Pre-sale US
Blue Frog Robotics 2014 0.18 Buddy No
Emotech LTD 2014 10 Olly No
Jibo 2012 72.7 Jibo No
Temi 2015 21 Temi No
ASUS – – Zenbo No
Groove X 2015 52.7 Lovot Japan
UBTech Robotics 2012 940 Lynx US
Zoetic AI 2017 – Kiki No
Yukai Engineering 2011 – BOCCO emo Japan
Innovation through Barrier Identification
Innovation research may be divided into two general areas of analysis: an economic-
oriented tradition and an organization-oriented tradition [43]. The first studies innovation
across countries and industrial sectors; for instance, through the sourcing of knowledge for
innovation [44], while the latter focuses on how specific new products are developed; the
structure and process by which organisations create products. This study focuses on the
latter since by analysing the product development process and identifying the innovation
inhibitors or barriers; it is possible to take action to eliminate them and restore the ‘natural
flow of innovation’ [45]. This approach is particularly useful for cutting-edge technologies
and new markets [46], such as the AR sector.
Market barriers to new technologies can be perceived in different ways [45]. For in-
stance, through the research, development and deployment perspective, we emphasise the
nature of the technology, its manufacture and user adoption [47,48]. Since this represents
the first line of the development process, much of the literature available around case
studies of AR focuses only on these elements of innovations. For instance, [49,50] or [51]
studied user needs, acceptability and usability of innovations in technology with end-users.
Numerous studies outline the critical technology targets for AR, drawing roadmaps for the
development of this sector and main research challenges (e.g., [13,28,38]).
None of these studies consider the development of assistive robots as a market-
orientated process; the obstacles of producing the technology from concept design to the
commercialisation of the AR. We argue, therefore, that since the application of robotics in
healthcare is not only an issue of technology or societal acceptance, but special attention
has also to be paid to broader market barriers and ways to overcome them. As a result,
this paper aimed to address the following question: what are the market barriers that are
inhibiting the development of AR?
To thoroughly understand the barriers, we have explored them from a market trans-
formation perspective. Here, we do not focus on the nature of the technology or typical
operating characteristics of conventional markets, but rather on the development of tech-
nology as part of a market process and what needs to be carried out in practical terms to
create markets for new technologies [47]. To date, most of the relevant literature centres
on market transformation studied in the eHealth sector, i.e., the use of information and
communication technologies in healthcare (i.e., [52–54]).
There is, therefore, a predominant focus only on software products. A distinction exists
between the development of a hardware product and its commercialisation. Consequently,
market barriers may also be different [55,56].
This study seeks to apply the Painuly (2001) framework, which builds upon the
barriers approach to innovation, focusing on a market transformation perspective [57].
Painuly developed a framework for analysing the barriers to renewable energy penetration
when this was an emerging sector. The study analysed the obstacles to creating a new
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and innovative market. The framework provides a methodology for identifying barriers
by reviewing case studies, including criteria for selection and measures to overcome the
barriers identified.
Different models describe product development processes for different industries.
Ulrich and Eppinger’s (2016) six phases of product development balance hardware and
software development in the product development process (Figure 2) [58]. The process
includes the tasks and responsibilities of the critical functions: marketing, design, and
manufacture. This model, along with Painuly’s (2001) framework, will serve as a basis of
our exploration of inefficiencies in the AR market.
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a d entrepreneurs be aware of the venture challenges and take measures to support these
inventions that are highly needed for the healthcare sector.
3. Methodology
Semi-structured interviews were conducted with 17 people from different assistive
robotic companies. The companies were based either in the UK or France (Table 2). The
interviews involved the owners of the company, wherever possible. Where this was not
possible, interviews were conducted with senior managers.
The study explored their perspectives relating to the challenges they perceived and
were facing during the product development and commercialisation process. Apart from
having to be involved in AR, the other criterion used to select businesses was the age of
the business. We aimed to obtain companies covering different business stages: seed and
development, start-up, expansion, and maturity.
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Table 2. Assistive robotic companies interviewed. (Note: – indicates that the company did not share the information).




Trading Country Product Description
1–10 July-18 0.24 5.6 No UK Wheelchair robotic arm
1–10 January-18 0.74 5.6 No UK Therapeutic robot
1–10 November-17 0.91 – No UK Emergency drone
1–10 September-17 1.07 75 No France Medication reminder robot
1–10 August-17 1.16 – No UK Care support robot
1–10 August-17 1.16 28.5 No UK Medication delivery robot
1–10 May-17 1.41 11.2 No France Smart wheelchair
11–20 September-16 2.07 155 Yes France Care support robot
1–10 September-16 2.07 5 No France Assistive robotic arm
1–10 July-16 2.24 192.5 Yes France Care support robot
1–10 April-16 2.49 143.7 Yes France Telepresence robot
– January-16 2.74 – No France Medication delivery robot
1–10 July-15 3.25 50 Yes France Patient monitoring solution
1–10 November-14 3.91 7.2 Yes France Therapeutic robot
30–50 November-12 5.91 50.3 Yes France Indoor projector robot
11–50 November-11 6.91 162.5 No France Care support robot
41–50 2007 11.00 15,400 Yes France Robotic air qualitypurification
We interviewed start-ups and companies working from at least six months to up
to 11 years. This was intended in order to map the different obstacles assistive robotic
companies face during the market process/product development and life cycle. Sampling
comprised a mixture of purposive and convenience, given that companies had to meet our
selection criteria [59]. Participants were briefed about the nature of the study, participation
was entirely voluntary, and it was agreed that companies would not be mentioned by name.
To design and structure the questions for the interview, we drew on Ulrich and
Eppinger’s (2015) six phases of product development. The process includes the tasks and
responsibilities of the critical functions of the company for each phase, including marketing,
design, and manufacture. The linearity of the process allowed us to structure the interview,
but it did not unduly restrain or influence the conversation. In this sense, interviews were
semi-structured and akin to Kvale’s notion of conversations with a purpose [60]. For each
of these stages, several questions were elaborated.
The questions were designed following the study objectives: explore AR market
barriers from the perspective of the companies, the critical functions of the development
process and an initial literature review from AR projects [61]. Examples of questions
include ‘What was the most difficult part during the phase of product planning?’, ‘What
was the biggest challenge in assessing customer needs?’, ‘Tell me about the problems you
faced during your prototype testing phase’. Follow up questions were asked to explore the
participants’ answers in more depth.
Interviews lasted between 20 and 50 min and were audio recorded. They started
with an introduction of the objectives of the study and by the participant’s overview of
their business.
Then, interviews were transcribed using IBM Watson Speech to text. The transcripts
were cleaned and put into a standardised format. The general inductive approach was
used to analyse the transcripts to identify themes in the text that were related to the
study evaluation objectives [61]. The analysis started with a close reading of the text,
and the themes were developed, which in the view of the investigators captures core
messages reported by participants, particularly around barriers and market inefficiencies.
Overlapping and redundant themes were reduced through a search of subtopics, including
different points of view and new insight. To show when companies perceived the effects
of the barriers, we also classified themes according to their appearance in the product
development process. Nineteen significant themes were identified, hereafter referred to as
barriers, and are described in the next section.
4. Discussion
The present paper follows [57] for classifying the nineteen themes identified. Follow-
ing the Painuly categorisation system, we organise the themes into five distinct sets of
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market barriers, shown in Table 3. Besides, by his classification scheme, Table 4 shows the
elements or the leading examples of the barrier impact in the AR market. Figure 3 displays
barrier emergence during the product development process.
Table 3. Barriers for AR companies.
Barrier Category Barrier Remarks
Market Failure
Access to the healthcare sector ‘without contacts, there is not really a way into it’
Highly fragmented healthcare sector
‘there are many different people involved’, ‘you can’t get to
the people that make the choices’, ‘is quite hard to reach
the client’
Poor market infrastructure ‘you have to manufacture where the skills are’
Distrust in entrepreneurs
‘people see us as buyers, instead of people trying to help
others doing what we love’, ‘doors are not open to
entrepreneurs with good ideas’
High investment requirements ‘is not cheap, is an expensive journey’, ‘this stop people fordoing, the cost puts an extra weight’
Economic and Financial
High cost of capital ‘bring a project together and fund that project is reallyreally difficult’
Lack of/inadequate access to capital ‘there are not investment opportunities for hardware’
High up-front capital costs for investors ‘there is great risk involved in fundinghardware companies’
Lack of access to credit for the consumer ‘[the product] might be too expensive for the final user’,‘you need to work on B2B’
Small market size ‘we don’t know how the UK [healthcare] systems work’,‘we will need someone to help us get to that market’
Institutional
Lack of institutions and mechanisms ‘there is a lack of directives’, ‘government supportis minimal’
Lack of a legal/regulatory framework ‘AI should be transparent’, ‘[healthcare segment] theyare reluctant’
Lack of stakeholders’ involvement in
decision making
‘this is a problem, we got the solution, and no one listen
[to entrepreneurs]’
Lack of universities’ participation
‘you can’t put a price [university support] but,
unfortunately, they are not interested in
product development’
Lack of a clear certification process ‘we cannot pursue a medical certification’
Technical
Lack of skilled care personnel ‘they haven’t seen a robot, so they don’t know how to use it’
Systems constraints ‘[challenge] to know what technology to use’, ‘integrate allthe technology is the main problem’
Social, Cultural and
Behavioural
Lack of consumer acceptance ‘is quite hard to reach the client’, ‘is not here to takepeople jobs’
Unfounded moral and ethical concerns of AR ‘[invest time] to convince people to have the robot’, ‘is notgoing to spy you’
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Table 4. Elements of identified barriers.
Barriers Barrier Elements
1. Market Failure
Access to the healthcare sector Access to patients for product co-creation. Disrupts the wholedevelopment process.
Highly fragmented healthcare sector Different stakeholders and organisations. Slows downtechnology acquisition.
Poor market infrastructure Lack of manufacture opportunities in Europe. Increases final product costand slows technology acquisition.
Distrust in entrepreneurs Disrupts the development process and technology adoption.
High investment requirements High seed funding needed to develop prototypes. Builds an entry barrierfor entrepreneurs. Discourages entrepreneurs.
2. Economic and Financial
High cost of capital
Fundamental differences between software and hardware investment
requirements. Creates a lack of capital, high-interest rates, and risk
perception by financial organisations. Impacts on economic viability.
Lack of/inadequate access to capital No awareness of hardware development implications. Impacts marketcompetition and market efficiency.
High up-front capital costs for investors High seed funding need increases risk perception. Lack of understandingof AR investment needs.
Lack of access to credit for the consumer High product cost. Under-developed credit market. Reduces market size.
Market size small
Fragment healthcare system between regions and countries. Prevents
product scale and potential gains, reducing the appeal for entry
of newcomers.
3. Institutional
Lack of institutions and mechanisms
Missing agencies at the planning level to support AR development.
Inhibits information dissemination between producers and consumers,
creating extra costs for companies.
Lack of a legal/regulatory framework Generates liability and concerns in the adoption of new technology.
Lack of stakeholders’ involvement in decision making No seeking of the involvement of developers. Creates misplaced priorities,making policymaker bodies unaware of the market barriers.
Lack of universities’ participation Impacts on recruitment and R&D opportunities.
Lack of a transparent certification process No clear the path for certification of AR devices. Disrupts market entry ofnew products.
4. Technical
Lack of skilled care personnel Slows down technology adoption, creates extra expenses.
Systems constraints Integration problems with healthcare IT infrastructure. Producers cannotrealise the market.
5. Social, Cultural and Behavioural
Lack of consumer acceptance Fears surrounding the broader impact of AR, for example, fear of robotstaking jobs. Reduces the market size.
Unfounded moral and ethical concerns of AR Affects market size and technology adoption.
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These tables present a useful heuristic device as a means of understanding the nature
and scope of critical bar iers in the AR market, as evidenced in the interviews. However,
we recognise that the clas ification of bar iers shown in Table 3 is not rigid, that some of
the bar iers are inter elated, and that some bar iers can, arguably, belong in more than
one category and share a similar impact. That is why the remaining section discus es and
analyses these findings not as individual and independent elements, but as members of
each barrier category.
4.1. Market Failure
This refers to the lack of conditions needed for perfect competition in the market,
most notably access to information. The impact of hereof can be seen through the whole
development process.
4.1.1. Access to Highly Fragmented Healthcare Sectors
The most frequent barrier identified was access to the healthcare industry. Specifically,
for innovation to take place, entrepreneurs need access to patients, families and carers’
needs, to know and understand their problems. Only with this knowledge is it possible to
generate and implement ideas for new improvements. User-centred design is seen as a vital
tool when it comes to AR innovation for healthcare, and its input could overcome further
barriers of adaptability and implementation. The interdisciplinary field of the innovation
process demands specialised knowledge in methods of care, presenting new challenges for
innovators who ask themselves whom they should involve in the process. Being able to
define and then access an ideally representative sample of early adopters for the market is
the initial challenge that AR companies face.
‘Without contacts, there is not a really a way into it [ . . . ] you are not exactly going to
be able to walk into any care home ask them; do you want a robot? Can we now work
with you?’
The fragmented structure of healthcare systems was seen as the primary reason for this
barrier since there is not a clear go-to point. Take, for instance, the National Health Service
(NHS) in the UK. Commonly seen as one entity, it is, in fact, a group of many individual
organisations: NHS England, NHS Scotland, NHS Wales, and the affiliated Health and
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Social Care in Northern Ireland, Public Health England, 195 Clinical Commissioning
Groups (CCGs), 245 hospital or acute trusts, around 7454 general practices only in England,
and thousands of community providers. Each often includes clinicians, financial managers,
commissioners and Information Technology managers.
Respondents mentioned that some health organisations charge for preliminary assis-
tance, even up to ‘GBP 1500 for a 3 h consultation’. Besides being an elevated price for new
ventures, 3 h is unrealistic about the actual time needed to gain sufficient understanding of
consumer needs. Every decision taken during the innovation process should count with
the feedback of lead-users and stakeholders involved. Some companies mentioned that for
conceptualisation, development and testing of their prototype product, consultation time
ranged between 10 and 15 h.
The alternative is to look to family and friends to become involved in the process.
This is a reason why so many entrepreneurs innovate around the needs of their relatives.
Participants also mentioned the extreme option of having to ‘look in the streets’ for potential
lead-users.
Distrust towards entrepreneurs was also mentioned as a barrier. Participants men-
tioned there was an expectation for eHealth entrepreneurs to have an extended portfolio of
developing robots as if they were app developers. Therefore, many mentioned that ‘doors
are not open to entrepreneurs with good ideas’.
‘We don’t have a reputation, or much more, products to our names, so that we can go
and say, this is a current problem, look what we have done, we got the solution . . . no
one listens’.
In particular, this last quotation illustrates the credibility problem these new en-
trepreneurs have in gaining acceptance in the eHealth marketplace.
What makes the mentioned lack of access different for AR companies compared to
digital companies is its combination with social, cultural and behavioural barriers. Where
digital technologies also suffer from negative attitudes and beliefs from the healthcare
members, individuals have been widely exposed to apps and programs in their daily
lives, greatly improving the user perception of the innovation and adoption of these
solutions [62,63]. Robots, on the other hand, have not yet had the same visibility. Com-
bined with this distrust towards entrepreneurs, we have a market that closes its doors to
technology and innovation—driven in part by ignorance, including uninformed ethical
concerns as well as cultural barriers. This restriction not only impacts the development pro-
cess but also businesses’ access to funding opportunities since cost-saving studies cannot
be carried out without healthcare support.
4.1.2. Complex Market Infrastructure
The complex structure of the healthcare system has a direct impact on our target
market infrastructure. According to interviewers, multiple people influence the procure-
ment process, making it challenging to identify and locate who is, ultimately, responsible
for making the final decision on a purchase or commission. Interviewers also mentioned
that the spread of AR technologies within healthcare systems is slow and fails to achieve
widespread use.
The number of individuals involved in the adoption process not only defines the
demand of the market but also slows down the diffusion of a product. It also raises a
fundamental problem: transparency regarding the structures and purchasing processes
within each organisation. This barrier has further impacts that discourage private funding
from supporting AR ventures.
‘[regarding the purchasing processes] for someone that is new to the market it is excep-
tionally difficult to get to the right people, to go to the people that make the choices’.
The lack of a technological appraisal tool or method for AR that could benefit com-
panies as a route to widespread use was also mentioned. There is currently a market
search friction problem; purchasing and supply agencies do not know what technologies
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are currently available. There is no standard platform for AR to prove their benefits to
healthcare stakeholders and look for potential buyers. Moreover, there are no distribution
channels for AR technologies.
‘it is quite hard to reach the client, and distributors ask for a lot of money, raising prices’.
Currently, initiatives such as Innovation, Health and Wealth, introducing a legal
obligation on all UK’s CCGs to offer National Institute for Health and Care Excellence
(NICE) approved technologies to patients, have a positive impact on new medicine use, but
it does not cover non-medicines [2]. Therefore, initiatives such as those should be designed
to overcome search friction.
4.2. Economic and Financial
This category describes those barriers which had an impact on the access to finance
and the conditions attached to obtaining financial backing. From the interviews, it was
clear that the main barriers focused on the lack of seed funding with implications for
scalability of the market. These issues have a significant impact during the first stages of
the development process (Figure 3).
4.2.1. Capital and Investment
According to interviewees, on average, three to four prototypes are required before
obtaining a minimum viable product. This could translate into four years of work and at
least three rounds of funding. This demonstrates that it is not only the technical challenges
that discourage AR innovation but also economic viability considerations. The fear of
financial failure appears to be thwarting most projects before they properly have the chance
to flourish.
As in other markets, robotics companies frequently start with entrepreneurs working
part-time on their projects. However, while app developers can find solutions to avoid
incurring initial costs, for robotics start-ups, the scope here is more limited. A high initial
investment is needed for buying off-the-shelf devices, as well as fast prototyping tools.
‘Finance, is so difficult, is not cheap, is an expensive journey, and this stops people from
doing it’.
Several participants explained that there is an underdeveloped capital market, scarcity
of capital, restricted entry, unavowed regulations and lack of access to affordable capital for
AR ventures. Others mentioned that there were few investors and venture capital providers
who understood hardware development and therefore, the seed capital needed. Those
who are willing to invest perceive this as a high-risk involvement, demanding high-interest
rates to offset the risks they take.
There is poor creditworthiness for AR and inadequate recovery regulations. Without
a repayment history, credit score or available assets, financial institutes perceive early-stage
AR companies as a high-risk investment. This translates into high interest rates and low
credit limits. This has a direct impact in particular on indebted businesses. AR companies
are often forced to recover through the sale of the collaterals, which in this market is the
manufacturing equipment or the technology inside the robot, not allowing a real recovery
for start-ups.
The lack of openness from the healthcare sector makes it difficult for start-ups to prove
cost-savings of their products, how they affect the right treatment and the downstream
healthcare system. Besides, assistive robots have an impact on the quality of life of patients
(i.e., therapeutic robots for reducing isolation, stress, anxiety), making it difficult to define
the real value of innovation without standard technological appraisal tools. Additionally,
participants’ views were that health commissioning bodies take their investment decisions
motivated more on cost and risk concerns than the healthcare outcomes for patients.
However, it was also noticed that companies interviewed were not aware of funding
opportunities provided by the European Union through their various initiatives (e.g., [64]).
Further research is needed to understand whether or not companies perceived these EU
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initiatives as convenient for their business development, or whether there are blockers or
challenges for companies to access these funding opportunities.
4.2.2. Customer Credit Facilities and Market Size
The cost of acquisition and use of assistive robots was reported as a significant barrier.
Business to consumer schemes are not viable for most companies since final AR products are
commonly too expensive for their end-users due to the costs associated with manufacturing
and the technology behind the product. Even if consumers want to purchase AR products,
because of under-developed credit facilities, this could present a barrier. Thus, currently,
there are no government policies, strategies and incentives for encouraging the adoption
of AR technologies that extend to offering either credit facilities or other elements of
financial support.
On the other hand, due to the complex structure of healthcare systems, the end-user
generally has no input on pricing considerations, only purchasing and supply agencies.
Therefore, if the product has not been prescribed, the final user will have to pay the full
price for a product, irrespective of affordability. All of this has an impact on the current
market size for AR companies.
Healthcare systems around the world not only vary in their structures and entry
channels but also in terms of their regulations and economic context, different leadership
styles and environments. Product or service development strategies may need to be tailored
to each unique system. This makes access to new markets, i.e., ones with which the eHealth
entrepreneur is not familiar, difficult. Interview responses indicated that companies from
France and the UK did not have any knowledge about the other’s healthcare market, and
both mentioned that they could not enter a new market without support. Some companies
mentioned difficulties expanding to other regions within the same country due to the
fragmented structure of the healthcare sector.
4.3. Institutional
Since AR in the healthcare sector represents an emerging market, policies and govern-
ments are still playing a catch-up game concerning regulation and support. We refer here to
the notion of institutional burdens, that is underdeveloped or absent institutional structures
which can hinder aspiring entrepreneurs from exploiting opportunities fully [65].
4.3.1. Poor Legislation, Poor Policies
The AR market lacks specialised agencies at a planning level that can develop and
ensure a safety adoption framework for AR innovations. As mentioned in Section 4.1.2,
there is lack of transparency in the purchasing and adoption procedure of new technologies
for the healthcare sector, starting with initial go-to points for entrepreneurs. The absence of
adequate appraisal tools makes it difficult for start-ups to assess the economic evaluation
of their products, which generally have an impact on the quality of life of patients (i.e.,
therapeutic robots for reducing isolation, stress, anxiety).
In the same way, there is no education for health stakeholders of the technology
available and opportunities this new market presents. Besides, liability concerns interrupt
the development process and AR adoption. All of this is compounded by a missing
regulatory body that supports early-stage companies, regulates the development process,
and promotes the adoption of assistive robots.
A lack of planning and the absence of policies to foster the development of innovations
in the eHealth sector was also mentioned. Barriers such as access to health experts and
lead users could be overcome with the right regulatory body. It could also address the
absence of legislation surrounding liability while testing or adopting new AR products at
the organisational and health professional levels. This includes critical appraisal tools for
testing AR, approved by the relevant bodies.
These barriers are the result of the reduced involvement that the supply side has in
decision making. Different from traditional markets, the healthcare stakeholders’ coun-
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terparts do not involve engineers, developers, and entrepreneurs in the development of
policies for innovations. There is currently a consultation culture missing, driven by a
tension surrounding change alongside social, cultural and behavioural barriers, described
in Section 4.5.
Another essential subject mentioned was the lack of support for entrepreneurs to
protect the intellectual property (IP) of their products. The current process takes around
five years to complete and requires a substantial investment in applications for patents and
design rights. In the UK, only one in twenty applications get a patent without professional
support. Subsequently, this might need to be renewed on an annual basis. This problem
prevents companies from accessing quality manufacturers recognised by the healthcare
industry, which often requires IP before getting involved in the process.
4.3.2. Lack of University Participation
Most companies that took part in this study mentioned the vital role that universities
played in this market, from access to technical and medical knowledge to the recruitment
of new talent. Nevertheless, it was acknowledged that doors are not open to entrepreneurs
and businesses.
‘You can’t put a price [university support] but, unfortunately, they are not interested in
product development’.
Moreover, current policies from some of the universities mentioned during the inter-
views highlighted the regulations against university spinout. Companies believe that some
universities currently retain intellectual property over any technological development.
Therefore, if an entrepreneur wants to apply the research carried out, they will have to
address the corresponding payback to the university.
Universities’ investment and support for AR companies is visible on launchpads
and incubators. Besides, previous studies have evidenced that IP-based spin-offs are
an ideal mechanism for technology transfer [66]. However, following the interviewers’
answers, universities should be more flexible about their current IP policies towards spin-
offs. Therefore, further research is needed to provide fair public policies for all the parties
involved [67].
4.3.3. Lack of a Transparent Certification Process
Navigating the tricky channels to obtain medical certification was regarded by the
businesses interviewed as burdensome and costly.
A device must receive a Conformitè Europëenne (CE) mark as a medical device
before being used in the healthcare sector of the European Economic Area [68]. In the
U.S., the Food and Drug Administration (FDA) regulates the sale of medical device prod-
ucts [69]. Certification is mandatory, and it is the manufacturer’s sole responsibility to
obtain approval. Overall, to obtain a certification, the manufacturer must follow conformity
assessment procedures depending upon the classification of the medical device. Several
factors are considered, such as usage time, lifespan, whether it is invasive, and more [68].
The higher the requirements, the tighter the controls applied to the device. If required,
conformity assessment needs to be undertaken by a certified entity designated by the
national regulatory body.
For all classes of device, the manufacturer is required to provide a technical file [68].
Therefore, having a quality management system (QMS) is one of the first steps to ensure
you meet compliance [70]. The QMS for Medical Devices or ISO 9001 contains around
fifty to several hundred procedures depending on the complexity of your product and
process. Therefore, companies need the knowledge and experience to complete diverse
reports and records, the Technical File for CE marking or 510 K for submission to the FDA
for US markets [68,69].
None of the companies younger than five years considered it worth the effort. Most
companies mentioned that understanding, meeting and measuring the regulation require-
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ments translates into a cost AR companies cannot afford. For the companies, there is no
transparent process to get their products certificated.
Therefore, instead of looking for medical certification, most companies only seek and
achieve conformity with the CE marking standards that rule the use of products sold within
the European Economic Area. To put this in perspective, this means most of these AR
companies follow the same procedure as toy manufacturers. The practical implication of
this choice is that doctors cannot prescribe toys and medical insurance do not recognise
toys either. Therefore, the patient should have to cover the full cost of the product.
We mentioned in previous sections the lack of an appraisal tool. Existing legal and
regulatory systems, initially designed for medicine, have not been adapted to the character-
istics of AR. However, most importantly, they do not allow entrepreneurs and start-ups to
enter and meet requirements without creating significant expenses.
4.4. Technical
This category discusses technological viability for AR in the healthcare market, not
state of the art challenges. It includes barriers for the adoption due to the nature of
these technologies.
Skilled Health Personnel and System Constraints
There appears to be a gap in the provision of education and training of healthcare
professionals regarding AR, as all the companies interviewed currently trading said they
had to spend time and money training healthcare professionals and carers on how to use
their products. It seemed that this could be addressed by improving the curriculum of
healthcare staff.
This acts as one constraint for the adoption of new technologies. Integration problems,
such as obsolete data records, or other current software being used as per regulatory
requirements in health settings also slows down the development process of RAS. The
lack of infrastructure was also a concern; the availability of resources such as connectivity
to the internet in remote healthcare organisations or directly with the final user, limit the
market further.
4.5. Social, Cultural and Behavioural
This category describes the opposition from the healthcare professionals to AR, the
willingness of the healthcare stakeholders to incorporate AR into their work environment
and care of patients.
Consumers’ Acceptance and Ethical Concerns
Attitudes and beliefs were seen as a crucial barrier for the market, slowing the intro-
duction of assistive robots in healthy environments. There is currently a distrust in AR
companies, enhanced by a lack of understanding of how the final product works. This
impacts on stakeholders’ understanding of the benefits and opportunities from AR.
The current distrust is also driven by concerns over patient safety, but also strong
resistance from staff to change their current practices, considering AR will disorder the
delivery of care. Some concerns were also raised about the belief among healthcare
professionals that robots will take their jobs.
Furthermore, ethical concerns were mentioned concerning AR and its underpinning
technology, to include robots’ levels of autonomy, and more general concerns around
automation. This fear of automation and AR is leading to an industry that is technology
lagging and consequently, the sector and crucially patients are missing out on these ad-
vances. The consequence for eHealth start-ups is that they have to commit their resources,
to face the market misconceptions of AR.
Education is a critical aspect. Like many other implementation evaluation studies [71],
better education has been seen as a facilitator for the eHealth market. Skills-related barriers,
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such as healthcare professionals’ and end-users’ technological abilities and experience, also
influence the implementation and acceptance of AR.
5. Conclusions
Given the potential of assistive robotics (AR) to improve lives, and upon a backdrop
of concerns around growing costs in health services, research on the adoption of AR in a
health care setting is still minimal. There is a clear need for research into improving the
efficiency of the AR marketplace [15]. The need to identify persisting innovation barriers
in the health industry has also been recognised by the European Innovation Partnership.
Thus, while the entry of AR into the mainstream healthcare sector has been constrained by
a range of obstacles slowing down the adoption of the technology, to our knowledge, no
research explores this issue specifically for this high-tech market.
The presented work presented new insight into and addressed the source and nature
of the barriers that are inhibiting a more rapid and widespread adoption of advances in
AR in healthcare.
Identifying market barriers has clear policy relevance. Addressing these barriers,
policymakers could increase the entrepreneurship and boost the performance of the sector.
Our goal is to raise awareness of these barriers, that further research may be conducted and
that policymakers may develop a sustainable framework that ensures AR and associated
technologies are realised in the healthcare sector.
Some of the main findings are in agreement with previous research that identifies
barriers in the adoption of digital technologies in eHealth and the co-evolutionary and
path-dependent nature of the innovation process more generally [5]. However, the impact
of our identified barriers in the AR market, and crucially, their interaction, is more far-
reaching than for digital companies in eHealth. Since this represents a new market for the
healthcare sector, there are several policy gaps impacting the development process and the
procurement and adoption of assistive robots.
There is a need to strengthen bonds to sources of specific and codified knowledge in
more traditional industries [72]. Fostering a culture of collaboration, involvement, educa-
tion, and communication have been seen as ways of overcoming healthcare stakeholders’
opposition to digital innovations [73,74]. The concerns about liability, patient privacy,
and security, also mentioned in studies regarding digital technologies [75,76], could be
addressed through the introduction of institutes and legislation, designed solely for AR de-
velopment. This also involves making a transparent, affordable, and accessible certification
process for assistive technologies.
All of these show that to address the significant barrier of access to the healthcare
sector, governments have to take a more proactive role. To overcome market failure or
inefficiencies that result from these barriers government intervention is vital [77]. From the
creation of legislation and policies to the establishment of open standards for the devel-
opment of AR, governments could sustainably facilitate the implementation of assistive
robots in different healthcare environments. Governments can also subsidise AR and
provide seed funding with positive externalities [78].
However, this governmental effort should be a joint effort among different countries.
Supportive legislation to ease the adoption of innovation among healthcare systems from
different countries should be encouraged. Only then can the real potential of AR be realised,
providing the companies with new opportunities, expanding the size of their market. As a
result, venture capital firms, angel investors, crowdfunding providers and other financial
backers will start reducing their risk perception.
Although we presented a comprehensive evaluation of market barriers, further re-
search is needed, in particular in other types of regions, including less developed economies.
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